Medibio Company

Medibio (ASX: MEB) (OTCQB: MDBIF) is a digital health company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio’s depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio’s application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio’s technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Founded in Perth, Australia with offices located in Melbourne (Vic), with U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market and
Technology: diagnostics
Industry: Biotechnology, Health Care, Health Diagnostics
Headquarters: Melbourne, Victoria, Australia
Founded Date: 31778
Employees Number: 11-50
Funding Status: IPO
Acquisitions Number: 1
Investors Number: 1
Total Funding: $31.4M
Estimated Revenue: Less than $1M
Last Funding Date: 2020-06-10
Last Funding Type: Undisclosed

Visit Website
Register and Claim Ownership